PCSK9 inhibitor

This page covers all PCSK9 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PCSK9.

Targets

PCSK9

Phase 3 pipeline (12)

• VCT220 Tablet · Vincentage Pharma Co., Ltd · Cardiovascular
  VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.
• SHP615 · Shire · Cardiovascular
  SHP615 is a monoclonal antibody targeting the PCSK9 protein.
• LCS16 · Bayer · Cardiovascular
  LCS16 is a small molecule that inhibits the PCSK9 enzyme.
• evolocumab and LDL apheresis · Hospital General Universitario Gregorio Marañon · Cardiovascular
  Evolocumab works by binding to PCSK9, a protein that regulates LDL cholesterol levels in the blood, thereby reducing LDL cholesterol production in the liver.
• cTIV or eTIV_a · Novartis · Cardiovascular
  cTIV is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.
• RP103 · Amgen · Cardiovascular
  RP103 is a monoclonal antibody targeting PCSK9.
• Treatment Prevention for Secondary CV · Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Cardiovascular
  This drug targets the PCSK9 protein to lower LDL cholesterol levels.
• LCS12 · Bayer · Cardiovascular
  LCS12 is a small molecule that inhibits the PCSK9 enzyme.
• SYH2053/placebo injection · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Cardiovascular
  SYH2053 is a monoclonal antibody targeting PCSK9.
• Evolocumab AI/pen · Amgen · Cardiovascular
  Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
• Placebo to Evolocumab · Amgen · Cardiovascular
  Evolocumab works by binding to PCSK9, a protein that regulates cholesterol levels in the blood, thereby increasing the levels of HDL and reducing the levels of LDL.
• Treatment with PCSK9 inhibitors · Beijing Anzhen Hospital · Cardiovascular
  PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors, thereby increasing LDL receptor availability on liver cells to remove more LDL cholesterol from the blood.

Phase 2 pipeline (5)

• Alirocumab Injectable Product · Wolfson Medical Center · Cardiovascular
  Alirocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower low-density lipoprotein cholesterol.
• AMG 193 · Amgen · Cardiovascular
  AMG 193 is a monoclonal antibody targeting PCSK9.
• AGN-210961 Formulation 5 · Allergan · Cardiovascular
  AGN-210961 Formulation 5 is a medication that targets the PCSK9 protein to lower LDL cholesterol.
• AGN-210961 Formulation 7 · Allergan · Cardiovascular
  AGN-210961 Formulation 7 is a drug that targets the PCSK9 protein to lower LDL cholesterol.
• AMG 223 · Amgen Research (Munich) GmbH · Cardiovascular
  AMG 223 is a human monoclonal antibody that targets PCSK9.